An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients With Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)
Latest Information Update: 01 Jul 2024
At a glance
- Drugs Pegcetacoplan (Primary) ; Pegcetacoplan (Primary)
- Indications Thrombotic microangiopathy
- Focus Pharmacokinetics; Registrational
- Sponsors Swedish Orphan Biovitrum
- 07 May 2024 Planned primary completion date changed from 9 Jan 2026 to 19 Jul 2025.
- 14 Mar 2024 Planned End Date changed from 31 Mar 2024 to 9 Jan 2026.
- 14 Mar 2024 Planned primary completion date changed from 31 Mar 2024 to 9 Jan 2026.